183 related articles for article (PubMed ID: 24700061)
21. Long-Term Safety and Curvature Deformity Characterization in Patients Previously Treated with Collagenase clostridium Histolyticum for Peyronie's Disease.
Goldstein I; Lipshultz LI; McLane M; Hu Y; Xiang Q; Liu G; Vijayan S; Gelbard MK
J Urol; 2020 Jun; 203(6):1191-1197. PubMed ID: 31922462
[TBL] [Abstract][Full Text] [Related]
22. Letter: Comparison of Collagenase
Desouky E; Levine LA
J Urol; 2024 May; 211(5):708-709. PubMed ID: 38382016
[No Abstract] [Full Text] [Related]
23. Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute-Phase Peyronie's Disease.
Nguyen HMT; Anaissie J; DeLay KJ; Yafi FA; Sikka SC; Hellstrom WJG
J Sex Med; 2017 Oct; 14(10):1220-1225. PubMed ID: 28874331
[TBL] [Abstract][Full Text] [Related]
24. Collagenase Clostridium histolyticum for the pharmacological management of Peyronie's disease.
Anaissie J; Powers MK; Hellstrom WJ; Yafi FA
Drugs Today (Barc); 2015 Aug; 51(8):457-68. PubMed ID: 26380384
[TBL] [Abstract][Full Text] [Related]
25. Second cycle of intralesional Collagenase Clostridium histolyticum for Peyronie's disease using the modified shortened protocol: Results from a retrospective analysis.
Capece M; Arcaniolo D; Manfredi C; Palmieri A; De Sio M; Verze P; Fusco F; Longo N; Mirone V
Andrologia; 2020 Apr; 52(3):e13527. PubMed ID: 32003061
[TBL] [Abstract][Full Text] [Related]
26. Evaluating collagenase Clostridium histolyticum administration protocols in the treatment of Peyronie's disease.
Phillips D; Chan JYH; Flannigan R
Curr Opin Urol; 2020 May; 30(3):328-333. PubMed ID: 32235277
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie's disease (PD).
Carson CC; Sadeghi-Nejad H; Tursi JP; Smith TM; Kaufman GJ; Gilbert K; Honig SC
BJU Int; 2015 Nov; 116(5):815-22. PubMed ID: 25818264
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies.
Lipshultz LI; Goldstein I; Seftel AD; Kaufman GJ; Smith TM; Tursi JP; Burnett AL
BJU Int; 2015 Oct; 116(4):650-6. PubMed ID: 25711400
[TBL] [Abstract][Full Text] [Related]
29. Re: Surgical Correction of Persistent Peyronie's Disease following Collagenase Clostridium histolyticum Treatment.
Morey AF
J Urol; 2015 Sep; 194(3):761. PubMed ID: 26292883
[No Abstract] [Full Text] [Related]
30. Re: Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie's disease.
Dincer M; Serefoglu EC
J Sex Med; 2014 May; 11(5):1350. PubMed ID: 24602117
[No Abstract] [Full Text] [Related]
31. A state-of-art review on collagenase
Chung E; Scott S; Wang J
Expert Opin Biol Ther; 2020 Jun; 20(6):559-564. PubMed ID: 32345061
[No Abstract] [Full Text] [Related]
32. Re: Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie's disease.
Masterson T; Patel P; Ramasamy R
Int J Impot Res; 2020 Mar; 32(2):251-252. PubMed ID: 30745568
[No Abstract] [Full Text] [Related]
33. Re: Patient Perspectives on Peyronie's Disease: Results of Poststudy Interviews from a Phase 2 Trial of Collagenase Clostridium histolyticum.
Seftel AD
J Urol; 2019 Apr; 201(4):649. PubMed ID: 30653023
[No Abstract] [Full Text] [Related]
34. Re: Re: Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie's disease.
Tsambarlis P; Levine LA
Int J Impot Res; 2020 Mar; 32(2):257-258. PubMed ID: 31417157
[No Abstract] [Full Text] [Related]
35. Results of SMSNA Survey Regarding Complications Following Intralesional Injection Therapy With Collagenase Clostridium Histolyticum for Peyronie's Disease.
Yafi FA; Anaissie J; Zurawin J; Sikka SC; Hellstrom WJ
J Sex Med; 2016 Apr; 13(4):684-9. PubMed ID: 27045265
[TBL] [Abstract][Full Text] [Related]
36. CCH injections regarded effective by men with Peyronie's disease.
Thoma C
Nat Rev Urol; 2015 Dec; 12(12):654. PubMed ID: 26526755
[No Abstract] [Full Text] [Related]
37. Peyronie's Disease and Injectable Collagenase Clostridium histolyticum: Safety, Efficacy, and Improvements in Subjective Symptoms.
Yang KK; Bennett N
Urology; 2016 Aug; 94():143-7. PubMed ID: 27211926
[TBL] [Abstract][Full Text] [Related]
38. The Management of Penile Fracture: a Review of the Literature with Special Consideration for Patients Undergoing Collagenase Clostridium Histolyticum Injection Therapy.
Hughes WM; Natale C; Hellstrom WJG
Curr Urol Rep; 2021 Jan; 22(2):13. PubMed ID: 33471204
[TBL] [Abstract][Full Text] [Related]
39. Survey of patient and partner satisfaction following collagenase Clostridium histolyticum treatment for Peyronie's disease.
Anaissie J; Yafi FA; Traore EJ; Sikka SC; Hellstrom WJ
Andrology; 2017 Mar; 5(2):274-277. PubMed ID: 28187522
[TBL] [Abstract][Full Text] [Related]
40. Re: Clinical Efficacy of Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease by Subgroups: Results from Two Large, Double-blind, Randomized, Placebo-controlled, Phase III Studies.
Kadioglu A; Boyuk A; Salabas E
Eur Urol; 2015 Nov; 68(5):908-9. PubMed ID: 26460876
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
